Heidelberg Pharma has shared good news about their HDP-101 treatment for multiple myeloma, a type of blood cancer. This treatment is being tested on patients whose cancer has come back or hasn’t responded to other treatments. In their latest tests, two patients in a group called ‘cohort 8’ showed no signs of cancer cells in their blood or bone marrow. This is a great result, meaning the treatment worked very well for them. Seven patients were given a certain dose of the treatment, and all handled it well with no serious side effects. Four of these patients showed that the treatment was working in their bodies, with two showing the best possible response. A doctor from Heidelberg Pharma, Dr András Strassz, said they are very happy with these results. He mentioned that they’ve seen good responses in different groups of patients, and the quick response in cohort 8 is especially encouraging. They are now testing a higher dose in the next group of patients to see if it works even better. The tests are ongoing to check if the treatment is safe and works well for these patients.